Standout Papers

Oral Semaglutide and... 1994 2026 2004 2015 1.2k
  1. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (2019)
    Mansoor Husain, Andreas L. Birkenfeld et al. New England Journal of Medicine
  2. A genome-wide search for human type 1 diabetes susceptibility genes (1994)
    June Davies, Yoshihiko Kawaguchi et al. Nature
  3. Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy (2004)
    Anthony Barnett, Stephen C. Bain et al. New England Journal of Medicine
  4. Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus (1995)
    S. T. Bennett, Anneke Lucassen et al. Nature Genetics
  5. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial (2017)
    Christopher Sorli, Shin‐ichi Harashima et al. The Lancet Diabetes & Endocrinology
  6. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial (2017)
    Vanita R. Aroda, Stephen C. Bain et al. The Lancet Diabetes & Endocrinology
  7. A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives (2021)
    Josh Reed, Stephen C. Bain et al. Diabetes Metabolic Syndrome and Obesity
  8. Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER (2021)
    Ahmed M. Shaman, Stephen C. Bain et al. Circulation
  9. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin (2023)
    Julio Rosenstock, Stephen C. Bain et al. New England Journal of Medicine
  10. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (2025)
    Darren K. McGuire, Nikolaus Marx et al. New England Journal of Medicine

Immediate Impact

11 by Nobel laureates 12 from Science/Nature 88 standout
Sub-graph 1 of 18

Citing Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
2025 Standout
Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial
2025 Standout

Works of Stephen C. Bain being referenced

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
2020
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
2018

Author Peers

Author Last Decade Papers Cites
Stephen C. Bain 6975 3414 3488 246 11.2k
Guntram Schernthaner 6064 2851 2636 223 10.6k
Avraham Karasik 5316 3891 2199 126 10.5k
George Grunberger 6718 3201 3411 160 10.5k
Yasuhiko Iwamoto 4756 2698 2180 267 10.2k
B Charbonnel 6864 3248 2763 236 9.4k
William C. Duckworth 7076 3740 2931 198 12.7k
Soffia Guðbjörnsdóttir 7974 2213 3125 200 12.4k
Francesco Giorgino 5008 4203 2385 313 11.9k
Björn Eliasson 7898 2106 3003 299 12.5k
Eelco J.P. de Koning 2653 3849 3801 225 10.1k

All Works

Loading papers...

Rankless by CCL
2026